Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
MESH1-mediated coenzyme A degradation drives ferroptosis sensitivity and muscle pathology
Chao-Chieh Lin, Joshua Rose, Alexander A. Mestre, Chien-Kung Cornelia Ding, Ssu-Yu Chen, Sze Mun Choy, Kah Yong Goh, Weiyi Jiang, Wen Xing Lee, Qizhou Jiang, Yanting Chen, Tianai Sun, Jianli Wu, Yueqi Chen, Yunju Oh, Pyeonghwa Jeong, Jiyong Hong, Kenon Chua, Michael C. Fitzgerald, Guo-Fang Zhang, Hong-Wen Tang, Pei Zhou, Jen-Tsan Chi
Chao-Chieh Lin, Joshua Rose, Alexander A. Mestre, Chien-Kung Cornelia Ding, Ssu-Yu Chen, Sze Mun Choy, Kah Yong Goh, Weiyi Jiang, Wen Xing Lee, Qizhou Jiang, Yanting Chen, Tianai Sun, Jianli Wu, Yueqi Chen, Yunju Oh, Pyeonghwa Jeong, Jiyong Hong, Kenon Chua, Michael C. Fitzgerald, Guo-Fang Zhang, Hong-Wen Tang, Pei Zhou, Jen-Tsan Chi
View: Text | PDF
Research Article Cell biology Muscle biology

MESH1-mediated coenzyme A degradation drives ferroptosis sensitivity and muscle pathology

  • Text
  • PDF
Abstract

CoA facilitates fatty acid synthesis, energy production, gene regulation, and antioxidant function. While CoA biosynthesis is well characterized, the mechanisms governing CoA degradation remain poorly understood. Here, we identify the Metazoan Homolog of SpoT, MESH1, as a CoA phosphatase that dephosphorylates CoA at the 3′ position of the ribose ring to form dephospho-CoA. Recent studies have shown that CoA, similar to glutathione, is a cysteine-derived metabolite that protects cells against ferroptosis. Ferroptosis induced by blocking cystine import depletes CoA biosynthesis, while CoA restoration rescues cells from ferroptosis. We found that MESH1 knockdown preserved CoA levels by preventing its degradation, contributing to ferroptosis protection, indicating the bifunctional role of MESH1 in regulating CoA and previously reported NADPH. Mechanistically, MESH1 knockdown elevates CoA levels, maintaining a functional mitochondrial thioredoxin system, thereby preventing mitochondrial lipid peroxidation. In Drosophila, we found that dMesh1 overexpression leads to ferroptosis-mediated muscle atrophy, which can be rescued by increasing CoA and NADPH levels. Taken together, these findings establish MESH1 as a key phosphatase that governs ferroptosis sensitivity by coordinating CoA and NADPH homeostasis, unveiling a link between CoA degradation, mitochondrial integrity, and muscle health.

Authors

Chao-Chieh Lin, Joshua Rose, Alexander A. Mestre, Chien-Kung Cornelia Ding, Ssu-Yu Chen, Sze Mun Choy, Kah Yong Goh, Weiyi Jiang, Wen Xing Lee, Qizhou Jiang, Yanting Chen, Tianai Sun, Jianli Wu, Yueqi Chen, Yunju Oh, Pyeonghwa Jeong, Jiyong Hong, Kenon Chua, Michael C. Fitzgerald, Guo-Fang Zhang, Hong-Wen Tang, Pei Zhou, Jen-Tsan Chi

×

Figure 3

MESH1 knockdown maintains functional mitochondrial thioredoxin system upon erastin treatment.

Options: View larger image (or click on image) Download as PowerPoint

MESH1 knockdown maintains functional mitochondrial thioredoxin system u...
(A) Graphical abstract of CoA import in maintaining the mitochondrial thioredoxin system. (B) Ferroptocide (2 μM, a chemical inhibitor of thioredoxin) abolished the protective effects of MESH1 knockdown upon erastin treatment. HT-1080 cells were transfected with control or MESH1 siRNA for 2 days, treated with erastin for 18 hours, and quantified by Cell-Titer Glo assay. (C) Mitochondrial thioredoxin is required for the protective effect of MESH1 knockdown upon erastin treatment. HT-1080 cells were transfected with MESH1 siRNA or in combination with cytosolic thioredoxin (TXN1) or mitochondrial thioredoxin (TXN2) for 2 days, subjected to 24 hours of erastin treatment, and quantified by Cell-Titer Glo assay. (D) Mitochondrial CoA transporter (SLC25A42) is required for the protective effect of MESH1 knockdown. HT-1080 cells transduced with control or 2 independent SLC25A42 shRNAs were knocked down with MESH1 siRNA and erastin treatment for Cell-Titer Glo assay. (E) The lowering monomer/dimer ratio of PRDX3 upon erastin treatment was rescued by MESH1 knockdown. Further knocking down of COASY abolished the protective effect of MESH1 knockdown, as determined by Western blots. (F) Quantification of the monomer/dimer ratio of PRDX3 upon erastin treatment with or without MESH1 siRNA or in combination with COASY siRNA. (G) MESH1 knockdown lowered erastin-induced mitochondrial lipid peroxidation. HT-1080 cells knocked down by control or 2 independent MESH1 siRNAs were treated with erastin (2 μM, 20 hours) or supplemented with CoA and quantified by the mitochondrial lipid peroxidation (mitoPerOx) sensor. (C, F, and G) One-way ANOVA, Tukey’s multiple comparisons, n = 3 independent biological replicates. (B and D) Two-way ANOVA, Šidák’s multiple comparisons, n = 3 independent biological replicates; data are shown as mean ± SEM.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts